Skip to content
lifestyle.emphas.is
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Amneal Pharmaceuticals LLC
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
June 29, 2026
Amneal Reports First Quarter 2026 Financial Results
May 7, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 22, 2026
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
April 22, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
April 14, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 9, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026
April 7, 2026
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
April 7, 2026
Amneal to Participate in Upcoming Investor Conference
March 5, 2026
1
2
Next Page
→